Molnupiravir

Molnupiravir or lagevrio is a new antiviral drug which has recently undergone clinical trials for COVID-19 treatment, and other uses.

Evidence
There is no evidence yet of the use of molnupiravir in patients with ME/CFS.

Risks and safety
Largely unknown. Molnupiravir was approved in the United Kingdom for human use in late 2021.

Costs and availability
Molnupiravir is not yet FDA-approved, although approval is likely in 2022. The European Medicines Agency is conducting a rolling review of molnupiravir for COVID-19 and if had been approved by the UK's Medicines and Healthcare products Regulatory Agency. Molnupiravir is taken orally.

Articles and news

 * Sep 2021, A Daily Pill to treat Covid could be just Months Away Scientists Say - WebMD

Learn more

 * Molnupiravir - DrugBank
 * Molnupiravir - drugs.com